In 1947, the privately-held multinational company Kowa Company, Ltd. of Nagoya, Japan, established its pharmaceutical division in order to research, develop, manufacture and market over-the-counter (OTC) drugs, healthcare products, prescription medicines and medical devices.

Kowa’s wide variety of prescription medicines include oral agents for the treatment of cardiovascular diseases as our specialty segments, topical agents for eye and skin, and agents affecting the digestive organs.

Since the launch of its first retinal camera in 1962, Kowa has been devoted to producing the most innovative optical products and integrated technology solutions in the world.

Kowa ophthalmic diagnostics products set clinical standards for diagnosis of a wide range of ophthalmic conditions and have been designed and engineered to provide easy-to-use solutions for healthcare professionals, so that they can continue to offer the very best in patient care.

A leader in the Japanese Intra Ocular Lens (IOL) market the second largest market in the world Avansee^TM set new standards for quality and ease of use for monofocal and Toric preloaded intraocular lenses.

Kowa have also produced several ophthalmic solutions for a number of debilitating eye disorders (currently marketed in Japan only):

• Neosynesin Kowa 5% eye solution (phenylephrine hydrochloride) for mydriasis ─ for the purpose of diagnosis or treatment
• Hypadil Kowa 0.25% ophthalmic solution (nipradilol) for glaucoma and intraocular hypertension
• Zepelin ophthalmic solution (acitazanolast hydrate) for allergic conjunctivitis
• GLANATEC^® ophthalmic solution 0.4% (Ripasudil Hydrochloride Hydrate) for glaucoma and ocular hypertension

Diagnostic products

As one of the leading providers of ophthalmologic diagnostic solutions, Kowa is committed to advancing the technological and user-focused solutions in modern eye clinics.

By driving innovation for healthcare professionals and providing outstanding imaging technology, practitioners can continue to provide the best patient care.

Kowa’s range of ophthalmic diagnostic products include:

• Non-Mydriatic Retinal Cameras
• Combination Retinal Cameras
• Portable Retinal Cameras
• Software
• Refraction
• Diagnostic
• Anterior

Avansee

Avansee – the fully preloaded Intra Ocular Lens (IOL) injector system from Kowa.

Avansee was first launched in Japan in 2007.  The initial 3P spherical models were followed by a fully pre-loaded, single-use spherical Avansee injector system AvanseePreset in 2010.

AvanseePreset was originally launched in Germany and Italy in 2014, and has since gone on to enter Switzerland, Benelux, Austria, Greece and France.

The most recent additions to Kowa’s growing ophthalmology portfolio are the Avansee Preload1P and Avansee Preload1P Toric injector systems.  The Avansee Preload1P was launched in Japan in 2016 and entered the European market in early 2017, with the Avansee Preload1P Toric featuring its unique Progressive Axial Correction (PAC) technology entering in early 2020.

Kowa remain a leader in the Japanese IOL market, the second largest market in the world.

Setting clinical standards for a wide range of ophthalmic conditions.

Livazo

Livazo^®/Livalo^® pitavastatin is a fully synthetic and highly potent statin available across Asia, Europe, Latin America and North America. It is indicated for the reduction of elevated total cholesterol (TC) and low density lipoprotein cholesterol (LDL-C) in adult patients with primary hypercholesterolemia, including heterozygous familial hypercholesterolemia, and combined (mixed) dyslipidemia, when response to dietary and other non-pharmacological measures are inadequate.

Since its 2003 launch in Japan, pitavastatin has accumulated millions of patient-years of exposure and has confirmed its place in the statin armamentarium, particularly for patients who require high-density lipoprotein cholesterol (HDL-C) raising or where poly-pharmacy exists, with a risk of drug-to-drug interactions. More recently, a study conducted in Japan demonstrated that pitavastatin did not increase the risk of developing diabetes in a large group of patients with impaired glucose tolerance.

Pitavastatin is marketed in several European countries by our partner Recordati (primarily under the Livazo^® brand name). For  MENA it is marketed and distributed by Algorithm S.A.L.

For more information on ordering pitavastatin or for patient materials, please get in touch with our partners.

Algorithm SAL
https://www.algorithm-lb.com/home
Tel:+961 9 222 050

Recordati S.p.A
https://www.recordati.com/en/
+39 800 167 999

Downloads